Brief: Cidara Therapeutics Announces European Approval Of Rezzayo® (Rezafungin)

Cidara Therapeutics

22/12/2023 12:33

Dec 22 (Reuters) - Cidara Therapeutics Inc  CDTX.O :
    * CIDARA THERAPEUTICS ANNOUNCES EUROPEAN APPROVAL OF
REZZAYO®
(REZAFUNGIN) FOR THE TREATMENT OF INVASIVE CANDIDIASIS IN ADULTS
    * CIDARA THERAPEUTICS INC-ENTITLED TO RECEIVE MILESTONE
PAYMENT OF
ABOUT $11.14 MILLION FROM MUNDIPHARMA FOR EUROPEAN MEDICINES
AGENCY (EMA) APPROVAL
    * CIDARA THERAPEUTICS INC-REZAFUNGIN HAS BEEN GRANTED ORPHAN
DRUG
DESIGNATION FOR ITS USE IN TREATMENT OF INVASIVE CANDIDIASIS IN
EU
    * CIDARA THERAPEUTICS INC-UNDER LICENSING AGREEMENT, CIDARA
REMAINS ELIGIBLE TO RECEIVE ADDITIONAL POTENTIAL PAYMENTS OF UP
TO ABOUT $470 MILLION
    * CIDARA THERAPEUTICS INC-PARTNERED WITH MUNDIPHARMA, WHICH
HAS
COMMERCIAL RIGHTS TO REZAFUNGIN OUTSIDE U.S. AND JAPAN

Source text for Eikon:  ID:nGNX2mn8m 
Further company coverage:  CDTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))